Business Context and Reporting Period
This Form 6-K filing by Sanofi-Synthélabo, dated April 13, 2004, announces a strategic divestiture agreement with GlaxoSmithKline (GSK). The transaction is directly linked to Sanofi-Synthélabo's ongoing public offer to acquire Aventis, announced on January 26, 2004.
Key Financial Metrics and Transaction Details
- Transaction Consideration: EUR 453 million in cash, payable upon completion.
- Assets Divested: Worldwide rights to Arixtra (fondaparinux sodium) and Fraxiparine (nadroparine calcium), plus the manufacturing facility in Notre-Dame de Bondeville, France.
- Historical Sales (2003):
- Arixtra: EUR 24 million.
- Fraxiparine: EUR 319 million.
- Operational Impact: The Notre-Dame de Bondeville plant employs 650 people and specializes in injectable products.
- Clinical Trials: GSK will assume responsibility for ongoing Arixtra clinical trials.
Material Changes and Conditions
The closing of this divestiture is conditional upon two primary factors: the successful completion of Sanofi-Synthélabo's acquisition offer for Aventis and the receipt of requisite clearances from EU and US competition authorities. This filing does not provide updated revenue, profit, or cash flow figures for Sanofi-Synthélabo's consolidated operations, as it focuses solely on this specific asset sale.
Outlook, Risks, and Management Commentary
Management notes that the divestiture was initiated to satisfy regulatory requirements associated with the Aventis acquisition. The filing includes standard forward-looking statements, warning that actual results may differ due to risks beyond the company's control, including regulatory approvals and the success of the Aventis offer. No specific financial guidance or outlook for the remaining business was provided in this document.
Key Facts for Investor Verification
- Verify the status of the Sanofi-Synthélabo offer for Aventis, as the EUR 453 million cash inflow is contingent on its completion.
- Monitor regulatory clearance progress from EU and US competition authorities for both the Aventis acquisition and the GSK divestiture.
- Review the Form F-4 (Registration No. 333-112314) and related prospectuses for detailed terms of the Aventis exchange offer.
- Confirm the timeline for the transfer of the Notre-Dame de Bondeville facility and the 650 associated employees to GSK.